Xtant outlines $99M-$103M 2026 revenue guidance while integrating Dilon sales force (NYSE:XTNT)
· seekingalpha.com
Xtant Medical (XTNT) Q2 2026 earnings call recap: revenue, margins, guidance cut, and HEMOBLAST rollout impacts.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...